Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias

Sickle Cell Disease Clinical Trial

— FIRST  

Official title:

The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02041299
• Other study ID #: LA38-0411
• Status: Terminated
• Phase: Phase 4
• Start date: April 17, 2014
• Est. completion date: June 18, 2019

Study information

• Verified date: July 2021
• Source: Chiesi Canada Corp
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research is being done so that we can look at the safety and efficacy of deferiprone in people with sickle cell disease or other anemias. Deferiprone is a drug that removes iron from the body. We will be comparing deferiprone with deferoxamine, another drug that removes iron from the body.

Description:

Deferiprone (brand name Ferriprox®) is an iron chelator that is approved in the United States and over 60 other countries for the treatment of iron overload in patients with thalassemia, when other treatments are inadequate. This study has been designed to evaluate the efficacy, safety, and tolerability of deferiprone vs. deferoxamine in patients who have SCD or other anemias, and who require chelation because of the extra iron they are taking in through blood transfusions. About 300 people from North America, South America, Europe, and the Middle East will take part in this study. Participants will be randomized in a 2:1 ratio to receive therapy for 52 weeks with either deferiprone or deferoxamine, another type of iron chelator. Patients who are randomized to the deferiprone group can choose to get the drug as either tablets or liquid, and must take it three times daily. Patients who are randomized to the deferoxamine group will receive it as a subcutaneous infusion that lasts from 8 to 12 hours and is given 5 to 7 days per week. For both drugs, the starting dosage is based on how much extra iron they have taken in through transfusions in the last 3 months and on the severity of iron load, as measured by serum ferritin levels in the blood and by the amount of iron in the liver and the heart. For deferiprone, the starting dosage will be increased each week over the first 3 weeks; and for both drugs, the dosage may be adjusted up or down during the study based on the level of iron overload and on safety considerations. Patients will need to have their blood count checked every week for the first 26 weeks, then every other week for the remaining 26 weeks; they will also have to give a blood sample for more detailed safety testing every month; and to give a blood sample for the measurement of serum ferritin every 3 months. Every six months, they will undergo an ECG and an MRI scan, and will be asked to complete a quality of life survey. At the end of the 52 weeks, participants will be invited to enter a 2-year study in which all patients will receive deferiprone, including those who were randomized to receive deferoxamine in the first year.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 230
• Est. completion date: June 18, 2019
• Est. primary completion date: April 20, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

1. Male or female = 2 years of age;

2. Have sickle cell disease (confirmed by Hb electrophoresis or more specific tests) or other conditions with iron overload from repeated blood transfusions (see exclusion criteria for exceptions);

3. Baseline LIC >7 mg/g dw (measured by MRI);

4. Patients who have received no less than 20 transfusions of RBCs;

5. Patients who have received at least 1 transfusion per year in the last 2 years and who are expected to have a continuing requirement (based on Investigator's judgement) during the duration of the trial

Exclusion Criteria:

1. Thalassemia syndromes;

2. Myelodysplastic syndrome (MDS) or myelofibrosis;

3. Diamond Blackfan anemia;

4. Primary bone marrow failure;

5. Baseline LIC >30 mg/g dw (measured by MRI);

6. Unable or unwilling to undergo a 7 day washout period if currently being treated with deferiprone or deferoxamine or deferasirox;

7. Previous discontinuation of treatment with deferiprone or deferoxamine due to adverse events;

8. History or presence of hypersensitivity or idiosyncratic reaction to deferiprone or deferoxamine;

9. Treated with hydroxyurea within 30 days;

10. History of malignancy;

11. Evidence of abnormal liver function (serum ALT level(s) > 5 times upper limit of normal at screening or creatinine levels >2 times upper limit of normal at screening);

12. A serious, unstable illness, as judged by the Investigator, during the past 3 months before screening/baseline visit including but not limited to: hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic or immunologic disease;

13. Clinically significant abnormal 12-lead ECG findings;

14. Cardiac MRI T2* <10ms;

15. Myocardial infarction, cardiac arrest or cardiac failure within 1 year before screening/baseline visit;

16. Unable to undergo MRI

17. Presence of metallic objects such as artificial joints, inner ear (cochlear) implants, brain aneurysm clips, pacemakers, and metallic foreign bodies in the eye or other body areas that would prevent use of MRI imaging

Related Conditions & MeSH terms

• Anemia
• Anemia, Sickle Cell
• Iron Overload
• Other Anemias
• Sickle Cell Disease

Intervention

Drug:
• Deferiprone

• Deferoxamine

Locations

Country	Name	City	State
Brazil	Centro Infantil Boldrini	Campinas
Brazil	Hospital de Clínicas de Porto Alegre-HCPA,	Rio Branco
Brazil	Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO	Rio de Janeiro
Brazil	Casa de Saúde Santa Marcelina	São Paulo
Brazil	Universidade Federal de São Paulo	São Paulo
Canada	Hospital for Sick Kids	Toronto	Ontario
Egypt	Alexandria University	Alexandria
Egypt	Zagazig University	Alexandria
Egypt	Ains Shams University	Cairo
Egypt	Cairo University	Cairo
Egypt	Pediatric Hospital of Cairo University	Cairo
Egypt	Mansoura University Children's Hospital	Mansoura
Saudi Arabia	Asser Central Hospital	Abha
Saudi Arabia	King Abdulaziz University Hospital	Jeddah	Western Region
Saudi Arabia	King Khalid University Hospital	Riyadh
Tunisia	Farhat Hached Hospital, Hematology Department	Sousse
Tunisia	National Center for Bone Marrow Transplantation	Tunis	Bad Saadoun
Tunisia	Principal Military Hospital of Instruction of Tunis	Tunis
Turkey	Cukurova University	Adana
Turkey	Hacettepe University	Ankara
Turkey	Istanbul University	Istanbul
United Kingdom	Barts and The London	London
United Kingdom	Evelina Children's Hospital	London
United Kingdom	Hammersmith Hospital	London
United Kingdom	Imperial College Healthcare NHS Trust	London
United States	University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan
United States	Medical University of South Carolina	Charleston	South Carolina
United States	University of Illinois at Chicago	Chicago	Illinois
United States	Children's Hospital of Michigan	Detroit	Michigan
United States	Children's Hospital	New Orleans	Louisiana
United States	Children's Hospital Oakland	Oakland	California
United States	The Children's Hospital of Philadephia	Philadelphia	Pennsylvania
United States	Thomas Jefferson University	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
ApoPharma

Countries where clinical trial is conducted

United States,  Brazil,  Canada,  Egypt,  Saudi Arabia,  Tunisia,  Turkey,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Liver Iron Concentration (LIC)	LIC was measured by MRI. A score >7 mg/g dw is indicative of iron overload.	Change from baseline to Week 52
Secondary	Change From Baseline in Cardiac Iron	Cardiac iron is measured by MRI in milliseconds (ms). A score of less than 20 ms is indicative of cardiac iron overload.	Change from baseline to Week 52
Secondary	Change From Baseline in Serum Ferritin	Serum ferritin provides a measure of iron level in the blood. Normal levels of serum ferritin are under 300 µg/L for females and 400 µg/L for males.	Change from baseline to Week 52
Secondary	Change in Patient-reported Quality of Life, as Measured by the Short Form Health Survey (SF-36) or the Child Health Questionnaire (CHQ-PF50).	Adult patients completed the SF-36 questionnaire and minors completed the CHQ-PF50. These questionnaires yield a profile of functional health and well-being, based on 8 scales of physical and mental health measures: Physical Functioning, Role Limitations due to Physical Health, Bodily Pain, General Health Perceptions, Vitality, Social Functioning, Role Limitations due to Emotional Problems, and Mental Health (MH), and summary scores are produced for physical well-being and mental well-being. The summaries are scored from 0-100, with higher scores reflecting better outcomes.	Change from baseline to Week 52